{"entity":{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","aka":[],"tldr":"Cyclophosphamide is an alkylating chemotherapy that damages DNA in dividing cells. It is part of CHOP for lymphoma, AC for breast cancer and VAC for childhood sarcomas, clears lymphocytes before CAR-T and prevents graft-versus-host disease after transplant; bladder bleeding, infertility and secondary leukaemia are its harms.","summary":"Approved 1959. Backbone of CHOP/R-CHOP, AC/TC (breast), VDC/IE (Ewing), VAC (rhabdomyosarcoma), CVP, hyper-CVAD, EMA-CO; lymphodepletion before CAR-T; post-transplant cyclophosphamide for GVHD prophylaxis; low-dose metronomic use. Toxicities: myelosuppression, haemorrhagic cystitis (mesna), infertility, secondary leukaemia, cardiotoxicity at high dose.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Cyclophosphamide","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cyclophosphamide"}],"tags":["gap-fill","generic","who-essential"],"related":["mesna"],"cancers":["dlbcl","breast-hr-positive","tnbc","ewing-sarcoma","rhabdomyosarcoma","neuroblastoma","all-leukemia","multiple-myeloma","pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy","car-t","allogeneic-hsct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["dbcg-82bc","nct06097364","nct04529772","nct06717347","nct06911502","nct06413498","nct06091865","nct06091254","nct06045806","nct05888493","nct05371093","nct03407144","nct04663347","nct04542824","nct06480565","nct04792489","nct06253663","nct07124936","nct03709680","nct05826535","nct05201248","nct07589543","nct04920617","nct07730515","nct07510815","nct07617753","nct03907852","nct07149857","nct07617805","nct06119685","nct07480928","nct05283720","nct04245839","nct03836352","nct06093841","nct07627711","nct04836507","nct06564038","nct07500220","nct07627698","nct07641036","nct04416984","nct03725059","nct07523529","nct07502287","nct05624554","nct05999994","nct06389006","nct06966700","nct06797635","nct06112379","nct05406401","nct07598955","nct04623541","nct06890884","nct05673785","nct04390399","nct06500273","nct06947967","nct06425302","nct07551362","nct06072612","eclipse"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Cytoxan / Endoxan","modality":"Alkylating agent (oxazaphosphorine prodrug)","mechanism":"Activated by hepatic CYP2B6 to 4-hydroxycyclophosphamide/phosphoramide mustard, which cross-links DNA; acrolein by-product causes bladder toxicity.","approvals":[{"region":"US","year":1959,"indication":"Lymphomas, leukaemias, multiple myeloma, breast, ovarian, neuroblastoma, retinoblastoma and other cancers"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cyclophosphamide/","neighbours":{"drug":[{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/"},{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"alk-negative-anaplastic-large-cell-lymphoma","kind":"cancer","name":"ALK-negative anaplastic large cell lymphoma","route":"/cancers/alk-negative-anaplastic-large-cell-lymphoma/"},{"id":"alk-positive-anaplastic-large-cell-lymphoma","kind":"cancer","name":"ALK-positive anaplastic large cell lymphoma","route":"/cancers/alk-positive-anaplastic-large-cell-lymphoma/"},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/"},{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/"},{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/"},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/"},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/"},{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/"},{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/"},{"id":"monomorphic-epitheliotropic-intestinal-t-cell-lymphoma","kind":"cancer","name":"Monomorphic epitheliotropic intestinal T-cell lymphoma","route":"/cancers/monomorphic-epitheliotropic-intestinal-t-cell-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/"},{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/"},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/"},{"id":"plasmablastic-lymphoma","kind":"cancer","name":"Plasmablastic lymphoma","route":"/cancers/plasmablastic-lymphoma/"},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/"},{"id":"primary-effusion-lymphoma","kind":"cancer","name":"Primary effusion lymphoma","route":"/cancers/primary-effusion-lymphoma/"},{"id":"primary-testicular-lymphoma","kind":"cancer","name":"Primary large B-cell lymphoma of the testis","route":"/cancers/primary-testicular-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/"},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/"},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/"},{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/"},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/"},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"thymoma-type-b1-b2","kind":"cancer","name":"Type B1 and type B2 thymoma","route":"/cancers/thymoma-type-b1-b2/"},{"id":"thymoma-type-b3","kind":"cancer","name":"Type B3 thymoma","route":"/cancers/thymoma-type-b3/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"rejuv-paed-fertility-male","kind":"technology","name":"Fertility in boys and young men treated for cancer, including testicular tissue banking","route":"/technologies/rejuv-paed-fertility-male/"},{"id":"rejuv-paed-fertility-female","kind":"technology","name":"Fertility in girls and young women treated for cancer, including ovarian tissue freezing","route":"/technologies/rejuv-paed-fertility-female/"},{"id":"rejuv-paed-late-mortality","kind":"technology","name":"Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked","route":"/technologies/rejuv-paed-late-mortality/"},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/"},{"id":"ovarian-function-after-chemotherapy","kind":"technology","name":"Ovarian function after chemotherapy: who recovers, and when","route":"/technologies/ovarian-function-after-chemotherapy/"},{"id":"gvhd-prophylaxis","kind":"technology","name":"Preventing graft-versus-host disease, and what prevention costs","route":"/technologies/gvhd-prophylaxis/"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/"},{"id":"rejuv-paed-second-cancers","kind":"technology","name":"Second cancers after childhood cancer: the risk by treatment, and why it is falling","route":"/technologies/rejuv-paed-second-cancers/"},{"id":"rejuv-paed-teeth-and-face","kind":"technology","name":"Teeth, jaws and facial growth after treatment in childhood","route":"/technologies/rejuv-paed-teeth-and-face/"},{"id":"rejuv-recovery-cumulative-dose","kind":"technology","name":"The cumulative dose that decides whether it comes back","route":"/technologies/rejuv-recovery-cumulative-dose/"},{"id":"cardiac-biomarker-monitoring","kind":"technology","name":"Troponin and natriuretic peptide monitoring during cancer treatment","route":"/technologies/cardiac-biomarker-monitoring/"}],"trial":[{"id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/"},{"id":"nct06890884","kind":"trial","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","route":"/trials/nct06890884/"},{"id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/"},{"id":"nct05999994","kind":"trial","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","route":"/trials/nct05999994/"},{"id":"nct05862064","kind":"trial","name":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem","route":"/trials/nct05862064/"},{"id":"nct06480565","kind":"trial","name":"A Phase 1/2 Trial of ADI-270 in ccRCC","route":"/trials/nct06480565/"},{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/"},{"id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/"},{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/"},{"id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/"},{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/"},{"id":"nct07124936","kind":"trial","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","route":"/trials/nct07124936/"},{"id":"nct05624554","kind":"trial","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","route":"/trials/nct05624554/"},{"id":"nct05382338","kind":"trial","name":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","route":"/trials/nct05382338/"},{"id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","route":"/trials/nct05406401/"},{"id":"nct00718549","kind":"trial","name":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct00718549/"},{"id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/"},{"id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/"},{"id":"nct06045806","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","route":"/trials/nct06045806/"},{"id":"nct05201248","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","route":"/trials/nct05201248/"},{"id":"nct05283720","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","route":"/trials/nct05283720/"},{"id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/"},{"id":"nct06425302","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","route":"/trials/nct06425302/"},{"id":"nct04245839","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct04245839/"},{"id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/"},{"id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/"},{"id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/"},{"id":"acns0121","kind":"trial","name":"ACNS0121","route":"/trials/acns0121/"},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/"},{"id":"acns1422","kind":"trial","name":"ACNS1422","route":"/trials/acns1422/"},{"id":"nct04437160","kind":"trial","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","route":"/trials/nct04437160/"},{"id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","route":"/trials/nct02455141/"},{"id":"nct02830724","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","route":"/trials/nct02830724/"},{"id":"nct03190941","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","route":"/trials/nct03190941/"},{"id":"aews0031","kind":"trial","name":"AEWS0031","route":"/trials/aews0031/"},{"id":"ahl2011","kind":"trial","name":"AHL2011","route":"/trials/ahl2011/"},{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/"},{"id":"impassion030","kind":"trial","name":"ALEXANDRA / IMpassion030","route":"/trials/impassion030/"},{"id":"calgb-50303","kind":"trial","name":"Alliance/CALGB 50303","route":"/trials/calgb-50303/"},{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/"},{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/"},{"id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","route":"/trials/nct05296564/"},{"id":"arched","kind":"trial","name":"ARCHED","route":"/trials/arched/"},{"id":"nct06690840","kind":"trial","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","route":"/trials/nct06690840/"},{"id":"barbican","kind":"trial","name":"BARBICAN","route":"/trials/barbican/"},{"id":"nct06530303","kind":"trial","name":"Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer","route":"/trials/nct06530303/"},{"id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","route":"/trials/nct07523529/"},{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/"},{"id":"calgb-40603","kind":"trial","name":"CALGB 40603 (Alliance)","route":"/trials/calgb-40603/"},{"id":"nct07107217","kind":"trial","name":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","route":"/trials/nct07107217/"},{"id":"nct01275677","kind":"trial","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","route":"/trials/nct01275677/"},{"id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","route":"/trials/nct06680752/"},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/"},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/"},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/"},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/"},{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/"},{"id":"nct00557193","kind":"trial","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","route":"/trials/nct00557193/"},{"id":"nct00002658","kind":"trial","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","route":"/trials/nct00002658/"},{"id":"nct00016276","kind":"trial","name":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","route":"/trials/nct00016276/"},{"id":"nct04390399","kind":"trial","name":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct04390399/"},{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/"},{"id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/"},{"id":"nct04792489","kind":"trial","name":"DALY II USA/ MB-CART2019.1 for DLBCL","route":"/trials/nct04792489/"},{"id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","route":"/trials/dbcg-82bc/"},{"id":"nct02488967","kind":"trial","name":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","route":"/trials/nct02488967/"},{"id":"nct04920617","kind":"trial","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","route":"/trials/nct04920617/"},{"id":"nct07411599","kind":"trial","name":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela","route":"/trials/nct07411599/"},{"id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/"},{"id":"nct07627711","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07627711/"},{"id":"nct07551362","kind":"trial","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","route":"/trials/nct07551362/"},{"id":"nct07627698","kind":"trial","name":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","route":"/trials/nct07627698/"},{"id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/"},{"id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","route":"/trials/nct07500220/"},{"id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","route":"/trials/nct07641036/"},{"id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/"},{"id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/"},{"id":"nct07480928","kind":"trial","name":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07480928/"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/"},{"id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/"},{"id":"nct06229067","kind":"trial","name":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","route":"/trials/nct06229067/"},{"id":"nct07617805","kind":"trial","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","route":"/trials/nct07617805/"},{"id":"nct06550141","kind":"trial","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","route":"/trials/nct06550141/"},{"id":"enrich","kind":"trial","name":"ENRICH","route":"/trials/enrich/"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/"},{"id":"nct02890602","kind":"trial","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","route":"/trials/nct02890602/"},{"id":"euronet-phl-c2","kind":"trial","name":"EuroNet-PHL-C2","route":"/trials/euronet-phl-c2/"},{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/"},{"id":"flyer","kind":"trial","name":"FLYER","route":"/trials/flyer/"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/"},{"id":"gepardouze","kind":"trial","name":"GeparDouze / NSABP B-59","route":"/trials/gepardouze/"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/"},{"id":"goya","kind":"trial","name":"GOYA","route":"/trials/goya/"},{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/"},{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/"},{"id":"nct01174121","kind":"trial","name":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","route":"/trials/nct01174121/"},{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/"},{"id":"nct03150693","kind":"trial","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","route":"/trials/nct03150693/"},{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/"},{"id":"nct01117441","kind":"trial","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","route":"/trials/nct01117441/"},{"id":"jcog9801","kind":"trial","name":"JCOG9801","route":"/trials/jcog9801/"},{"id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","route":"/trials/nct04771871/"},{"id":"mosun-len-mzl","kind":"trial","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","route":"/trials/mosun-len-mzl/"},{"id":"nct04146298","kind":"trial","name":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","route":"/trials/nct04146298/"},{"id":"nct01057069","kind":"trial","name":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","route":"/trials/nct01057069/"},{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/"},{"id":"nct07016399","kind":"trial","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","route":"/trials/nct07016399/"},{"id":"nct06795503","kind":"trial","name":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","route":"/trials/nct06795503/"},{"id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","route":"/trials/nct04335669/"},{"id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","route":"/trials/nct06318897/"},{"id":"nct00109031","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","route":"/trials/nct00109031/"},{"id":"nct05269381","kind":"trial","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","route":"/trials/nct05269381/"},{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/"},{"id":"nct03907852","kind":"trial","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","route":"/trials/nct03907852/"},{"id":"polar-bear","kind":"trial","name":"POLAR BEAR","route":"/trials/polar-bear/"},{"id":"nct06802757","kind":"trial","name":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","route":"/trials/nct06802757/"},{"id":"nct06220032","kind":"trial","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","route":"/trials/nct06220032/"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/"},{"id":"nct00431080","kind":"trial","name":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","route":"/trials/nct00431080/"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/"},{"id":"nct06093841","kind":"trial","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","route":"/trials/nct06093841/"},{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/"},{"id":"nct00630032","kind":"trial","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","route":"/trials/nct00630032/"},{"id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/"},{"id":"nct03407144","kind":"trial","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","route":"/trials/nct03407144/"},{"id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/"},{"id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/"},{"id":"nct01985724","kind":"trial","name":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","route":"/trials/nct01985724/"},{"id":"nct00615602","kind":"trial","name":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","route":"/trials/nct00615602/"},{"id":"sjmb12","kind":"trial","name":"SJMB12","route":"/trials/sjmb12/"},{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/"},{"id":"nct05371093","kind":"trial","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct05371093/"},{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/"},{"id":"nct05447702","kind":"trial","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05447702/"},{"id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/"},{"id":"nct06253663","kind":"trial","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","route":"/trials/nct06253663/"},{"id":"nct03709680","kind":"trial","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","route":"/trials/nct03709680/"},{"id":"nct06797635","kind":"trial","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","route":"/trials/nct06797635/"},{"id":"nct03725059","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","route":"/trials/nct03725059/"},{"id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/"},{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/"},{"id":"nct02641847","kind":"trial","name":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","route":"/trials/nct02641847/"},{"id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/"},{"id":"nct01700946","kind":"trial","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","route":"/trials/nct01700946/"},{"id":"nct04301739","kind":"trial","name":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu","route":"/trials/nct04301739/"},{"id":"nct06389006","kind":"trial","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","route":"/trials/nct06389006/"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/"},{"id":"nct00136084","kind":"trial","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","route":"/trials/nct00136084/"},{"id":"nct03206671","kind":"trial","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","route":"/trials/nct03206671/"},{"id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/"},{"id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","route":"/trials/nct06291064/"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/"},{"id":"trog-99-03","kind":"trial","name":"TROG 99.03","route":"/trials/trog-99-03/"},{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/"}],"paper":[{"id":"paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022","kind":"paper","name":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","route":"/key-papers/paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022/"},{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/"},{"id":"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012","kind":"paper","name":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","route":"/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/"},{"id":"paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019","kind":"paper","name":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303","route":"/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/"},{"id":"paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017","kind":"paper","name":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial","route":"/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/"},{"id":"paper-casulo-pod24-follicular-lymphoma-jco-2015","kind":"paper","name":"Early relapse of follicular lymphoma after R-CHOP defines patients at high risk for death: an analysis from the National LymphoCare Study","route":"/key-papers/paper-casulo-pod24-follicular-lymphoma-jco-2015/"},{"id":"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997","kind":"paper","name":"EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients","route":"/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/"},{"id":"paper-flyer-four-vs-six-cycles-r-chop-lancet-2019","kind":"paper","name":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER)","route":"/key-papers/paper-flyer-four-vs-six-cycles-r-chop-lancet-2019/"},{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/"},{"id":"paper-graall-2005-huguet-jco-2018","kind":"paper","name":"GRAALL-2005: randomised hyperfractionated cyclophosphamide in a paediatric-inspired adult ALL protocol","route":"/key-papers/paper-graall-2005-huguet-jco-2018/"},{"id":"paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025","kind":"paper","name":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial","route":"/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/"},{"id":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","kind":"paper","name":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","route":"/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/"},{"id":"paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015","kind":"paper","name":"Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","route":"/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/"},{"id":"paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","kind":"paper","name":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","route":"/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/"},{"id":"paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019","kind":"paper","name":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","route":"/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/"},{"id":"paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","kind":"paper","name":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/"},{"id":"paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","kind":"paper","name":"Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)","route":"/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/"},{"id":"paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018","kind":"paper","name":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","route":"/key-papers/paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018/"},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/"},{"id":"paper-scalp-trial-jama-2017","kind":"paper","name":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","route":"/key-papers/paper-scalp-trial-jama-2017/"},{"id":"paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","kind":"paper","name":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","route":"/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/"}],"roadmap":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"term":[{"id":"alkylating-agent","kind":"term","name":"Alkylating agents and antimetabolites","route":"/terms/alkylating-agent/"},{"id":"rejuv-second-alkylating-agents-and-myeloid-neoplasms","kind":"term","name":"Alkylating agents and therapy-related myeloid neoplasms","route":"/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/"},{"id":"second-primary-bladder-after-cyclophosphamide","kind":"term","name":"Bladder cancer after cyclophosphamide","route":"/terms/second-primary-bladder-after-cyclophosphamide/"},{"id":"rejuv-second-choices-made-at-treatment","kind":"term","name":"Choices made at the time of treatment that change the second cancer risk","route":"/terms/rejuv-second-choices-made-at-treatment/"},{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/"},{"id":"lymphoma-tx-fertility-preservation","kind":"term","name":"Fertility before lymphoma treatment: what to ask for, and when","route":"/terms/lymphoma-tx-fertility-preservation/"},{"id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/"},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/"},{"id":"alopecia-persistent-chemotherapy","kind":"term","name":"Persistent chemotherapy-induced alopecia","route":"/terms/alopecia-persistent-chemotherapy/"},{"id":"rejuv-second-platinum-and-parp-inhibitors","kind":"term","name":"Platinum drugs and PARP inhibitors: the newer leukaemia risk","route":"/terms/rejuv-second-platinum-and-parp-inhibitors/"},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/"},{"id":"lymphoma-tx-car-t-pathway","kind":"term","name":"The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting","route":"/terms/lymphoma-tx-car-t-pathway/"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/"},{"id":"lymphoma-tx-tumour-lysis","kind":"term","name":"Tumour lysis syndrome in lymphoma: who is at risk, and rasburicase","route":"/terms/lymphoma-tx-tumour-lysis/"},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/"}],"idea":[{"id":"lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","kind":"idea","name":"Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America","route":"/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/"},{"id":"lymphoma-ev-the-drugs-that-cure-and-the-places-without-them","kind":"idea","name":"The drugs that cure lymphoma, and the places that do not have them","route":"/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/"}],"company":[{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/"}]}}